Long-Term SBP Prophylaxis: Trading Established Efficacy for Lower Resistance Risk
A cirrhotic patient recovering from a first SBP episode needs indefinite antibiotic prophylaxis. The choice between norfloxacin's longer track record and rifaximin's lower resistance-selection profile turns out to depend on a culture history nobody has checked yet.
Eleanor D., a 66-year-old woman, has led the same church choir for over fifteen years and returned to rehearsal the week after her hepatitis-related cirrhosis diagnosis three years ago, determined not to let it change her routine more than it had to. She was admitted ten days ago with her first episode of spontaneous bacterial peritonitis, confirmed on diagnostic paracentesis and treated to resolution with a week of intravenous antibiotics. Two details of her own chart shape what happens next more than the diagnosis does. Her creatinine is 0.8 and her renal function is normal, which removes the usual reason to steer away from an agent with systemic absorption and means neither candidate is being excluded on her kidneys. And she has no prior cultures on record — this was her first infectious episode — so there is no organism history to tell the team whether the local resistance pattern has already reached her, which is precisely the piece of evidence the argument below turns on and does not have. Now approaching discharge, the team is planning her long-term secondary SBP prophylaxis, which by every current guideline she should remain on indefinitely given her history and ongoing ascites.
The two agents typically considered here carry genuinely different track records. Norfloxacin has the longer, original trial base — Ginès and colleagues demonstrated reduced SBP recurrence in patients with her exact history, and that trial is still what the indefinite-prophylaxis recommendation rests on. Rifaximin, increasingly favored in practice for exactly this indication, has the advantage of a lower resistance-selection profile — a real consideration given that fluoroquinolone resistance among the organisms that actually cause SBP has risen substantially in the years since norfloxacin's founding trials, and she is looking at years, potentially the rest of her life, of daily exposure to whichever agent she starts.
An indefinite decision with a missing data point
I'd start norfloxacin. It has the longer, original trial base directly showing reduced SBP recurrence in patients with her exact history, and for an indefinite prophylaxis decision, I want the agent with the deepest evidence behind it, not just the one currently more fashionable in practice.
I'd lean toward rifaximin instead, and not on fashion — fluoroquinolone resistance among the gram-negative organisms that actually cause SBP has risen substantially since norfloxacin's original trials were run. She's likely looking at years of daily exposure to whichever drug she starts, and that cumulative selection pressure is exactly the kind of risk that doesn't show up in an older trial's original results, only in what's happened to resistance patterns since.
'Deepest evidence behind it' is true of norfloxacin's original trials, but those trials were run against the resistance landscape of their own era, and treating that evidence as equally applicable to today's landscape is exactly the assumption I'd push back on.
I don't think either of you should finalize this without checking something we haven't looked at yet — her own prior culture history. This is her first infectious episode, so we don't have one from this hospitalization, but if she's had any prior urinary or other cultures on record showing fluoroquinolone-resistant organisms, that would make this a much less close call in rifaximin's favor. Without that check, we're deciding on population-level resistance trends alone, when a more specific answer might already exist in her chart.
A chart review confirmed no prior culture history on record, leaving the population-level resistance argument as the deciding factor. Rifaximin was started for indefinite secondary SBP prophylaxis.
The hepatologist's preference for norfloxacin's established trial base was noted directly rather than treated as settled by the switch — if cost or access ever limits rifaximin's continued use, norfloxacin remains the documented fallback rather than requiring a fresh debate.